Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy

Sharon Grisaru-Tal, Marc E. Rothenberg, Ariel Munitz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Abstract

Eosinophils are important effector cells and therapeutic targets in allergic diseases. Emerging data indicate that eosinophils infiltrate a variety of solid tumor types and have pleiotropic activities by at least two non-mutually exclusive mechanisms: direct interactions with tumor cells, and intricate cross-talk with lymphocytes. In light of the immune checkpoint inhibition revolution in cancer therapy, we review eosinophil–lymphocyte interactions in the tumor microenvironment. We also analyze potential interactions between eosinophils and lymphocyte subsets, including T cells, natural killer cells and innate lymphoid cells. We provide perspectives on the consequences of these interactions and how eosinophils are accessory cells that can affect the response to various forms of T cell-mediated immunotherapies and might be therapeutically targeted to improve cancer immunotherapy.

Original languageEnglish
Pages (from-to)1309-1316
Number of pages8
JournalNature Immunology
Volume23
Issue number9
DOIs
StatePublished - Sep 2022

Funding

FundersFunder number
Azrieli Foundation Canada-Israel
Cancer Biology Research Center
Dotan Hemato Oncology fund
Richard Eimert Research Fund on Solid Tumors
Sunshine Charitable Foundation
US-Israel bi-national science foundation2015163
National Institutes of HealthR37 AI045898, P30 DK078392, R01 AI124355
National Institutes of Health
National Institute of Allergy and Infectious DiseasesU19AI070235
National Institute of Allergy and Infectious Diseases
Israel Cancer Research Fund
Israel Cancer Association
Israel Science Foundation886/15, 542/20
Israel Science Foundation
Tel Aviv University

    Fingerprint

    Dive into the research topics of 'Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy'. Together they form a unique fingerprint.

    Cite this